Manipulating Estrogenic/Anti-Estrogenic Activity of Triphenylethylenes towards Development of Novel Anti-Neoplastic SERMs
Selective estrogen receptor modulators (SERMs) act as estrogen receptor (ERα) agonists or antagonists depending on the target issue. Tamoxifen (TAM) (a non-steroidal triphenylethylene derivative) was the first SERM approved as anti-estrogen for the treatment of metastatic breast cancer. On the hunt...
Saved in:
Main Authors: | Heba E. Elnakib, Marian M. Ramsis, Nouran O. Albably, Merna A. Vector, Jan J. Weigand, Kai Schwedtmann, Jannette Wober, Oliver Zierau, Günter Vollmer, Ashraf H. Abadi, Nermin S. Ahmed |
---|---|
Format: | article |
Language: | EN |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/02806fab66f74a54bdf6c60bef1b845b |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene
by: Luigi Gennari, et al.
Published: (2010) -
Selective estrogen receptor modulators: tissue specificity and clinical utility
by: Martinkovich S, et al.
Published: (2014) -
Effect of estrogens on skin aging and the potential role of SERMs
by: Susan Stevenson, et al.
Published: (2007) -
Profiling of gene expression regulated by 17β-estradiol and tamoxifen in estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines
by: Rangel N, et al.
Published: (2017) -
Tumor suppressor ING4 inhibits estrogen receptor activity in breast cancer cells
by: Keenen MM, et al.
Published: (2016)